Drug
Alectinib clinical trials
Also written Alecensa, RO5424802 and RG7853.
- studies test it
- 52
- open now
- 16
- in phase 3
- 10
- first study started
- 2013
Keep track of what changes. Save the alectinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Alecensa
- 22
Studies by the year they started
52 studies that test it; most in 2020 (8)
| Year | Studies |
|---|---|
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 8 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 16
- Phase 2
- 35
- Phase 3
- 10
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 29
Hoffmann-La Roche (20) · Genentech, Inc. (3) · Massachusetts General Hospital (2) · China Medical University Hospital (2) · Instituto Nacional de Cancerologia de Mexico (2) · Cancer Research UK (2) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · Fondazione per la Medicina Personalizzata (1)
Often tested with
Tested in the same studies.
Atezolizumab (16) · Entrectinib (12) · Vemurafenib (12) · Cobimetinib (10) · Trastuzumab (8) · Erlotinib (7) · Pertuzumab (7) · Palbociclib (7)
Studies
Open first, then newest update. How each study uses alectinib is read from its arms, and is right about nine times in ten.
Testing it · 52
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 2Genentech, Inc.NCT04302025Written as Alectinib
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as Alectinib
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886Written as Alectinib
- A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)RecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07001384Written as Alectinib
- Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)Not yet recruitingPhase 1/2China Medical University HospitalNCT07560410Written as Alectinib
- Alectinib Pharmacokinetic in Patients With NSCLCRecruitingPhase 1/2Instituto Nacional de Cancerologia de MexicoNCT05713006Written as Alectinib Oral Product
- DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersRecruitingPhase 2/3Cancer Research UKNCT05770037Written as Alectinib
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as Alectinib
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Written as Alectinib 150 MG
- Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNot applicableGuangdong Association of Clinical TrialsNCT06709274Written as Alectinib
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as Alectinib
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingPhase 2Hunan Province Tumor HospitalNCT04322890Written as Alectinib 150 MG
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Alectinib
- Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib BloodlevelsRecruitingPhase 4University Medical Center GroningenNCT05525338Written as Alectinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Alectinib
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200Written as Alectinib
- A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerActive, not recruitingPhase 3Hoffmann-La RocheNCT03456076Written as Alectnib
- A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompletedPhase 3Hoffmann-La RocheNCT03194893Written as Alectinib
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Alectinib
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3Hoffmann-La RocheNCT03178552Written as Alectinib
See all 52 studies that test alectinib →
Given in every arm · 4 — alectinib is usual care beside what is tested
- Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangementsRecruitingPhase 1/2Joshua PalmerNCT05987644Written as Alectinib
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Written as Alectinib
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingPhase 2AstraZenecaNCT03944772Written as Alectinib
- A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.CompletedPhase 1Hoffmann-La RocheNCT02023125Written as Alectinib
As the comparator · 2 — what is tested is compared with alectinib
Codes
What other systems call alectinib · ClinicalTrials.gg INT006325
- MeSH (NLM) C582670alectinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) LIJ4CT1Z3YALECTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1727455Confirmed FDA, Wikidata
- Wikidata Q21099132alectinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C101790AlectinibOne source FDA
- DrugBank DB11363One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582670 | alectinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | LIJ4CT1Z3Y | ALECTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1727455 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21099132 | alectinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C101790 | Alectinib | One source FDA |
| DrugBank | DB11363 | — | One source Wikidata |
Also registered as alectinib hydrochloride (UNII P9YY73LO6J · RxNorm 1727454).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.